Holen Sie sich die Stockscreener-App
3.19
1.92%
0.06
Handel nachbörslich:
3.19
Schlusskurs vom Vortag:
$3.13
Offen:
$3.12
24-Stunden-Volumen:
1.21M
Relative Volume:
4.60
Marktkapitalisierung:
$269.44M
Einnahmen:
$351.37M
Nettoeinkommen (Verlust:
$-135.96M
KGV:
-2.4922
EPS:
-1.28
Netto-Cashflow:
$-85.40M
1W Leistung:
+8.87%
1M Leistung:
+0.95%
6M Leistung:
-6.73%
1J Leistung:
+5.63%
1-Tages-Spanne:
$3.11
$3.315
1-Wochen-Bereich:
$3.04
$3.315
52-Wochen-Spanne:
$2.75
$4.60
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Firmenname
Atea Pharmaceuticals Inc
Sektor
Branche
Telefon
857-204-8109
Adresse
225 FRANKLIN STREET, BOSTON
Vergleichen Sie AVIR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
3.19 | 269.44M | 351.37M | -135.96M | -85.40M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-13 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-01-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-10-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-24 | Eingeleitet | JP Morgan | Overweight |
| 2020-11-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-11-24 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Atea Pharmaceuticals Inc Aktie (AVIR) Neueste Nachrichten
Atea Pharmaceuticals Faces Shareholder Revolt Over Director's Stock Sale, Strategic Decisions - StockTitan
Atea Pharmaceuticals engages Evercore to explore partnerships - MSN
Atea Pharmaceuticals, Inc. Engages Evercore to Identify Potential Opportunities to Enhance Shareholder Value, Including the Exploration of Strategic Partnerships Related to Its Phase 3-Ready Program for the Treatment of Hepatitis C Virus - Marketscreener.com
Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships - GlobeNewswire
Atea Pharmaceuticals Taps Evercore to Explore Strategic Options for Phase 3 HCV Program - StockTitan
Charles Schwab Investment Management Inc. Acquires 50,794 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals director Franklin Berger sells $1.02 million in stock By Investing.com - Investing.com Australia
Atea Pharmaceuticals director Franklin Berger sells $1.02 million in stock - Investing.com
Fmr LLC Buys 182,174 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - MarketBeat
Atea Pharmaceuticals stock hits 52-week low at $2.88 By Investing.com - Investing.com Australia
Atea Pharmaceuticals stock hits 52-week low at $2.88 - Investing.com
Atea Pharmaceuticals announces results from Phase 2 regimen of bemnifosbuvir - Yahoo Finance
Atea Aims For Underserved HCV Niche With Combo Regimen - News & Insights
After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study - Yahoo Finance
Atea reports high efficacy in Phase 2 HCV treatment study - Investing.com
Atea Pharmaceuticals Announces Positive Results from Phase - GlobeNewswire
Atea's HCV Drug Achieves 98% Cure Rate in Phase 2 Trial, Shows Breakthrough Promise - StockTitan
Atea plans Phase 3 study for hepatitis C drug after mid-stage results - Yahoo Finance
Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference - GlobeNewswire
Atea Pharmaceuticals CEO to Present at Evercore HealthCONx Conference | AVIR Stock News - StockTitan
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year? - MSN
Island Pharmaceuticals Advances Dengue Clinical Trial - MSN
Atomo Diagnostics Plans Share Issuance to Boost Capital - MSN
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024 - GlobeNewswire
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024 - GlobeNewswire Inc.
FMR LLC Increases Stake in Atea Pharmaceuticals Inc - GuruFocus.com
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) is BML Capital Management LLC's 3rd Largest Position - MarketBeat
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2024 Earnings Call Transcript - Insider Monkey
Atea Pharmaceuticals Advances in HCV Treatment Development - TipRanks
Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Atea Reports $31.2M Loss, Exits COVID Program Despite Strong HCV Pipeline Results | AVIR Stock News - StockTitan
Appian Cl A Sees RS Rating Improve To 72 - MSN
AVIRAtea Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Atea Pharmaceuticals (AVIR) to Release Quarterly Earnings on Thursday - MarketBeat
Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 - The Manila Times
Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024 - The Manila Times
Atea Pharmaceuticals to Present New Data Supporting the - GlobeNewswire
Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024 - StockTitan
SG Americas Securities LLC Increases Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Respiratory Syncytial Virus Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | GSK, MedImmune, ReViral, Pfizer, Sanofi, BioComo, Merck - The Globe and Mail
Morgan Stanley Upgrades Atea Pharmaceuticals (AVIR) - MSN
Atea Pharmaceuticals Leads The Charge In US Penny Stocks Spotlight - Simply Wall St
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? - Yahoo Finance
Dimensional Fund Advisors LP Buys 211,428 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
182,326 Shares in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Purchased by Marshall Wace LLP - MarketBeat
Atea Pharmaceuticals (AVIR) Loses -8.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Almitas Capital LLC Invests $4.27 Million in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - MarketBeat
Finanzdaten der Atea Pharmaceuticals Inc-Aktie (AVIR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):